LYEL Lyell Immunopharma Inc
- Stocks
- Healthcare
- NASDAQ: LYEL
Price (delayed)
$16.54
Market cap
$317.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$24.29
Enterprise value
$263.96M
Relative Growth:
Rel. Growth:
11
Relative Strength:
Rel. Strength:
82
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
22
Highlights
Lyell Immunopharma's debt has decreased by 13% YoY and by 4.6% QoQ
LYEL's quick ratio has dropped by 53% year-on-year but it is up by 2.7% since the previous quarter
The EPS has declined by 48% year-on-year but it rose by 2.8% since the previous quarter
The net income has dropped by 58% year-on-year
Lyell Immunopharma's equity has decreased by 47% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of LYEL
Market
Valuations
Earnings
Shares outstanding
19.21M
Market cap
$317.75M
Enterprise value
$263.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
4,616.53
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,980.42
Revenue
$53,000
Gross profit
$53,000
Operating income
-$356.17M
Net income
-$331.4M
EBIT
-$331.4M
EBITDA
-$315.12M
Free cash flow
-$172M
Per share
Balance sheet
Liquidity
EPS
-$24.29
EPS diluted
-$24.29
Free cash flow per share
-$11.63
Book value per share
$20.24
Revenue per share
$0
TBVPS
$26.06
Total assets
$385.45M
Total liabilities
$86.53M
Debt
$46.6M
Equity
$298.92M
Working capital
$245.31M
Debt to equity
0.16
Current ratio
7.65
Quick ratio
7.54
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-594,556.6%
Gross margin
100%
Net margin
-625,277.4%
Operating margin
-672,011.3%
Return on assets
-68.9%
Return on equity
-85.6%
Return on invested capital
-86.8%
Return on capital employed
-95.1%
Return on sales
-625,277.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYEL stock price
How has the Lyell Immunopharma stock price performed over time
Intraday
3.7%
1 week
-0.3%
1 month
-6.82%
1 year
-33.31%
YTD
29.22%
QTD
1.85%
Financial performance
How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$53,000
Gross profit
$53,000
Operating income
-$356.17M
Net income
-$331.4M
Gross margin
100%
Net margin
-625,277.4%
The net income has dropped by 58% year-on-year
The operating income has dropped by 58% year-on-year
The operating margin has dropped by 52% year-on-year and by 8% since the previous quarter
Lyell Immunopharma's net margin has shrunk by 52% YoY and by 8% QoQ
Price vs fundamentals
How does LYEL's price correlate with its fundamentals
Growth
What is Lyell Immunopharma's growth rate over time
Valuation
What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.82
P/S
4,616.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,980.42
The EPS has declined by 48% year-on-year but it rose by 2.8% since the previous quarter
The stock's P/B is 64% more than its last 4 quarters average of 0.5 but 37% less than its 5-year quarterly average of 1.3
Lyell Immunopharma's equity has decreased by 47% YoY and by 11% from the previous quarter
LYEL's price to sales (P/S) is 128% more than its 5-year quarterly average of 2021.8 and 33% more than its last 4 quarters average of 3460.8
The revenue has declined by 9% since the previous quarter but it has increased by 3.9% year-on-year
Efficiency
How efficient is Lyell Immunopharma business performance
The ROE has plunged by 157% YoY and by 16% from the previous quarter
Lyell Immunopharma's ROIC has plunged by 137% YoY and by 15% from the previous quarter
The ROA has dropped by 137% year-on-year and by 13% since the previous quarter
The return on sales has dropped by 52% year-on-year and by 8% since the previous quarter
Dividends
What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYEL.
Financial health
How did Lyell Immunopharma financials performed over time
LYEL's quick ratio has dropped by 53% year-on-year but it is up by 2.7% since the previous quarter
The current ratio has dropped by 53% year-on-year but it rose by 2.1% since the previous quarter
Lyell Immunopharma's debt is 84% lower than its equity
The debt to equity has surged by 78% year-on-year and by 7% since the previous quarter
Lyell Immunopharma's equity has decreased by 47% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.